Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Ref Type | Journal Article | ||||||||||||
| PMID | (31764178) | ||||||||||||
| Authors | Zhao XS, Zhou J, Dong L, Zhang H, Ye YJ | ||||||||||||
| Title | Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation. | ||||||||||||
|
|||||||||||||
| URL | |||||||||||||
| Abstract Text | |||||||||||||
| Molecular Profile | Treatment Approach |
|---|
| Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
|---|
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|
| Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
|---|
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ARID1A Q1327* | pancreatic ductal adenocarcinoma | predicted - sensitive | Olaparib | Case Reports/Case Series | Actionable | In a clinical case study, Lynparza (olaparib) treatment resulted in an objective response with 40% decrease in the diameter of the lesion and a progression-free survival of at least 13 months in a patient with pancreatic ductal adenocarcinoma harboring ARID1A Q1327* along with KRAS G12R, TP53 R273C, and CBL A463V (PMID: 31764178). | 31764178 |